Imunoterapija dijabetesa tipa 1

master's thesis

• Title (english): Immunotherapy of diabetes type 1
• Author: Katarina Lalić
• Mentor: Roberta Petlevski (mentor)
• Committee member: Roberta Petlevski (predsjednik povjerenstva)
• Committee member: Donatella Verbanac (član povjerenstva)
• Committee member: Lidija Bach-Rojecky (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of medical biochemistry and haematology); Zagreb
• Defense date and country: 2022-06-27, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Medical Biochemistry

Abstract

Dijabetes tipa 1 (DT1) je autoimuna endokrinološka bolest koja nastaje kao posljedica uništenja β stanica gušterače koje proizvode hormon inzulin. Uzrokom razvoja DT1 smatra se kombinacija okolišnih i genetskih čimbenika koji dovode do autoimunosti posredovane u najvećoj mjeri autoreaktivnim T limfocitima. Trenutna terapija DT1 nadomjescima inzulina liječi posljedicu bolesti bez ostvarivanja učinka na očuvanje β stanica. Imunoterapija bi usmjeravanjem prema različitim sastavnicama imunosnog sustava mogla djelovati direktno na uzrok DT1. Najveći potencijal u održavanju remisije DT1 pokazuju teplizumab, alefacept i antitimocitni globulini, a djelovanje sva tri imunoterapijska pristupa usmjereno je prema sprječavanju aktivacije T limfocita. Unatoč pozitivnim rezultatima trenutno ni jedan oblik imunoterapije nije odobren za liječenje DT1.

Abstract (english)

Diabetes type 1 (DT1) is an autoimmune endocrine disease that results from the destruction of insulin producing pancreatic β cells. The cause of DT1 development is considered to be a combination of environmental and genetic factors that lead to autoimmunity mediated mostly by autoreactive T lymphocytes. Current DT1 insulin replacement therapy treats the consequences of the disease without having an effect on β cell preservation. Immunotherapy, by targeting different components of the immune system, could act directly on the cause of DT1. Teplizumab, alefacept and antithymocyte globulins show the greatest potential in maintaining DT1 remission, and the action of all three immunotherapeutic approaches is aimed at preventing T lymphocyte activation. Despite the positive results, currently no form of immunotherapy is approved for the treatment of DT1.

• Keywords: dijabetes tipa 1; imunoterapija
• Keywords (english): diabetes type 1; immunotherapy
• Language: croatian
• URN:NBN: urn:nbn:hr:163:182553
• Study programme: Title: Medical biochemistry; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra medicinske biokemije (magistar/magistra medicinske biokemije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2022-07-14 15:43:09